An innovation that has kickstarted a revolution in the study and practice of health care is getting even more attention. Three scientists who pioneered the discovery and development of glucagon-like peptide-1 (GLP-1)-based obesity treatments have been named 2024 Lasker Award winners.
Following the recent recommendation of its advisory committee, the U.S. FDA gave the nod to Zevra Therapeutics Inc.’s arimoclomol, a day ahead of its Sept. 21 PDUFA date, as the first treatment for Niemann-Pick disease type C (NPC), a rare genetic disease linked to progressive neurological symptoms that is almost always fatal. Branded Miplyffa, it is indicated for use in combination with enzyme inhibitor miglustat in adults and children, ages 2 and older.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Achilles Therapeutics, Basilea Pharmaceuticals.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Bavarian Nordic, Ensysce Biosciences, Longboard Pharmaceuticals, Vanda Pharmaceuticals, Xspray Pharma.
By treating mice with antifibrotic drugs, researchers were able to stave off functional decline of the ovaries. Six weeks of systemic treatment with the antifibrotic pirfenidone, which is approved for the treatment of idiopathic pulmonary fibrosis, in early middle age improved both the morphology and the endocrine function of the animals’ ovaries at 1 year of age.
The U.S. Court of Appeals for the Federal Circuit reined in a district court that invalidated three claims in an Astellas Pharma Inc. patent protecting bladder drug Myrbetriq (mirabegron) based on a issue that was never argued.
What comes down must go up seems to be the rule of thumb these days, even for U.S. FDA fees. The cost of using a priority review voucher (PRV) to shave four months off an FDA standard 10-month drug review has dropped drastically over the past several years. But come Oct. 1, biopharma companies will have to pay nearly 89% more than on the previous day to use a PRV.
RSS
